Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia

Akira Ito, Yuko Kuga, Hiroyuki Honda, Hiroyuki Kikkawa, Atsushi Horiuchi, Yuji Watanabe, Takeshi Kobayashi

Research output: Contribution to journalArticle

246 Citations (Scopus)

Abstract

Anti-HER2 antibody can induce antitumor responses, and can be used in delivering drugs to HER2-overexressing cancer. Previously, we produced hyperthermia using magnetite nanoparticles that generate heat in an alternating magnetic field. In the present study, we constructed anti-HER2 immunoliposomes containing magnetite nanoparticles, which act as tumor-targeting vehicles, combining anti-HER2 antibody therapy with hyperthermia. The magnetite nanoparticle-loaded anti-HER2 immunoliposomes exerted HER2-mediated antiproliferative effects on SKBr3 breast cancer cells in vitro. Moreover, 60% of magnetite nanoparticles were incorporated into SKBr3, and the cells were then heated at 42.5°C under an alternating magnetic field, resulting in strong cytotoxic effects. These results suggest that this novel therapeutic tool is applicable to treatment of HER2-overexpressing cancer.

Original languageEnglish
Pages (from-to)167-175
Number of pages9
JournalCancer Letters
Volume212
Issue number2
DOIs
Publication statusPublished - Aug 30 2004

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia'. Together they form a unique fingerprint.

  • Cite this

    Ito, A., Kuga, Y., Honda, H., Kikkawa, H., Horiuchi, A., Watanabe, Y., & Kobayashi, T. (2004). Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Letters, 212(2), 167-175. https://doi.org/10.1016/j.canlet.2004.03.038